Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sagopilone infusion duration in recurrent ovarian cancer
NCT00246688Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of sagopilone in ovarian cancer (2 arms), sponsored by Bayer. Primary endpoint: Proportion of responders at 18 weeks. Started Nov 2005; status: completed.
02
Drugs
sagopilone
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00246688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246688.